In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation scientists is achieving the right pharmacological profile, particularly around solubility, bioavailability and absorption.
As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. These changes boost surface area and enhance solubility, but they also produce powders that are notoriously difficult to handle, dose, and manufacture using traditional volumetric filling systems. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer.
Pharmaceutical companies don’t create difficult powders by accident. During clinical development, powders are deliberately micronised, spray‑dried or structurally engineered to maximise solubility and bioavailability. Spray drying, for example, can be used to generate amorphous or hollow particles that dissolve far more rapidly than crystalline forms, but often at the cost of flowability and bulk density.
These “challenging” powder characteristics are a direct consequence of optimising for pharmacological performance rather than manufacturability.
A critical distinction often gets overlooked: pharmacological formulation and manufacturing formulation are not the same.
In early drug development, formulation work focuses on ADME - absorption, distribution, metabolism and excretion. Scientists finetune particle size, structure and composition to ensure the drug reaches the right target at the right concentration in a biologically active form. Manufacturing formulation considerations should not hold back these early stages.
However, conventional volumetric filling systems can force teams to think about manufacturability too early. This often leads to time consuming, expensive reformulation efforts that may compromise drug performance.
The Fill2Weight Gravimetric Powder Filler allows new powders with challenging powder properties to be dosed consistenty and repeatably. For smaller volume productions it can be used from R&D through to clinical and commercial production. For larger volume productions it can be used for early phase work, delaying the requirement for manufacturing formulation until sufficient confidence in the formulation is achieved.
Fill2Weight eliminates the need to reformulate solely to accommodate filling equipment. Instead of relying on predictable powder flow, the proprietary technology behind 3P innovation’s Fill2Weight gravimetric platform doses by true mass, ensuring accuracy even with low‑density, poorly flowing or structurally complex powders.
This gives formulation teams the freedom to:
• Preserve the original pharmacological design
• Adjust particle attributes as new pharmacokinetic data emerges
• Transition between clinical phases more rapidly
• Avoid unnecessary reformulation driven purely by manufacturing limitations
In essence, Fill2Weight gives formulation freedom - allowing teams to optimise for the patient, not the production line.
Clinical trial delays can exceed $1 million per day1. Reformulating to suit volumetric filling systems adds time, cost, regulatory complexity and may even reduce drug performance.
Fill2Weight helps teams:
• Enter human trials sooner
• Respond quickly to pharmacokinetic insights
• Advance through clinical phases without pausing to redesign formulations for conventional filling equipment
Data rich AI driven target discovery methods are making the initial stages of drug discovery easier but are resulting in increasingly complex and poorly soluble compounds especially within small molecules. The biggest challenge is no longer finding effective compounds - it’s delivering them successfully within the body.
Fill2Weight supports this new reality by adapting to the drug, rather than forcing the drug to adapt to the equipment. For teams navigating today’s solubility and bioavailability challenges, Fill2Weight is more than a filling solution; it is a strategic enabler of faster, more flexible and more effective clinical development.
Reference
How Much Does a Day of Delay in a Clinical Trial Really Cost? | Applied Clinical Trials Online